IRIS
MARTORA, FABRIZIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.367
NA - Nord America 2.434
EU - Europa 2.377
SA - Sud America 536
Continente sconosciuto - Info sul continente non disponibili 119
AF - Africa 75
OC - Oceania 5
Totale 9.913
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.288
SG - Singapore 1.813
CN - Cina 1.113
RU - Federazione Russa 1.076
DE - Germania 573
VN - Vietnam 483
BR - Brasile 444
IT - Italia 306
HK - Hong Kong 257
IN - India 189
BD - Bangladesh 153
KR - Corea 130
FR - Francia 105
FI - Finlandia 92
JP - Giappone 79
CA - Canada 62
GB - Regno Unito 49
NL - Olanda 48
AR - Argentina 45
MX - Messico 41
ES - Italia 26
IQ - Iraq 25
ZA - Sudafrica 22
UA - Ucraina 20
EC - Ecuador 16
ID - Indonesia 16
PK - Pakistan 16
AT - Austria 15
PH - Filippine 15
PL - Polonia 14
IE - Irlanda 12
TH - Thailandia 11
KE - Kenya 10
MA - Marocco 9
TR - Turchia 9
CR - Costa Rica 8
CI - Costa d'Avorio 7
TW - Taiwan 7
VE - Venezuela 7
CL - Cile 6
DZ - Algeria 6
IL - Israele 6
JM - Giamaica 6
LT - Lituania 6
OM - Oman 6
RS - Serbia 6
EG - Egitto 5
HN - Honduras 5
MY - Malesia 5
PY - Paraguay 5
SE - Svezia 5
UY - Uruguay 5
AE - Emirati Arabi Uniti 4
DO - Repubblica Dominicana 4
JO - Giordania 4
NI - Nicaragua 4
TT - Trinidad e Tobago 4
BO - Bolivia 3
BY - Bielorussia 3
CO - Colombia 3
EE - Estonia 3
KZ - Kazakistan 3
PA - Panama 3
RO - Romania 3
SY - Repubblica araba siriana 3
UZ - Uzbekistan 3
AF - Afghanistan, Repubblica islamica di 2
AL - Albania 2
AZ - Azerbaigian 2
CZ - Repubblica Ceca 2
DK - Danimarca 2
GH - Ghana 2
GN - Guinea 2
GT - Guatemala 2
KH - Cambogia 2
KW - Kuwait 2
MR - Mauritania 2
PE - Perù 2
PR - Porto Rico 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
TN - Tunisia 2
AM - Armenia 1
AU - Australia 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BE - Belgio 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BS - Bahamas 1
BW - Botswana 1
CG - Congo 1
CH - Svizzera 1
CV - Capo Verde 1
ET - Etiopia 1
GM - Gambi 1
GR - Grecia 1
HR - Croazia 1
HT - Haiti 1
KG - Kirghizistan 1
Totale 9.780
Salva come PNG Salva come JPEG
Città #
Singapore 971
Hefei 614
San Jose 518
Moscow 282
Hong Kong 247
Santa Clara 229
Ashburn 208
Beijing 170
Ho Chi Minh City 147
Kochi 131
Munich 128
Seoul 122
Hanoi 114
Krefeld 113
Los Angeles 82
Lauterbourg 78
The Dalles 73
Tokyo 71
Helsinki 53
Bad Bellingen 50
Milan 50
New York 50
São Paulo 47
Naples 46
Council Bluffs 43
Dallas 43
Redondo Beach 38
Buffalo 32
Rome 25
Da Nang 21
Brooklyn 20
Chicago 20
Lappeenranta 20
Orem 20
Mexico City 19
Atlanta 18
Seattle 18
Boston 16
Haiphong 16
Toronto 15
Chennai 14
Nuremberg 14
Rio de Janeiro 13
Boardman 12
Houston 12
Phoenix 12
Denver 11
Dublin 11
Frankfurt am Main 11
London 11
Baghdad 10
Belo Horizonte 10
Biên Hòa 10
Montreal 10
Turku 10
Curitiba 9
Poplar 9
Falkenstein 8
Nairobi 8
Warsaw 8
Amsterdam 7
Brasília 7
Campinas 7
Florence 7
Guayaquil 7
Kronberg 7
Salvador 7
San José 7
Washington 7
Xi'an 7
Bắc Giang 6
Johannesburg 6
Jyväskylä 6
Lahore 6
Memphis 6
Milwaukee 6
Mumbai 6
Paris 6
Porto Alegre 6
Pune 6
Ribeirão Preto 6
Rochdale 6
San Francisco 6
Turin 6
Vienna 6
Ankara 5
Can Tho 5
Grand Rapids 5
Ha Long 5
Hải Dương 5
Manchester 5
Montevideo 5
New Delhi 5
Newark 5
Salt Lake City 5
San Bernardino 5
Santo André 5
Shanghai 5
Zhengzhou 5
Amman 4
Totale 5.425
Salva come PNG Salva come JPEG
Nome #
Effect of Dupilumab on Sexual Desire in Adult Patients with Moderate to Severe Atopic Dermatitis 469
Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study 402
Comprehensive Molecular Analysis of Disease-Related Genes as First-Tier Test for Early Diagnosis, Classification, and Management of Patients Affected by Nonsyndromic Ichthyosis 171
Management of Psoriasis Patients with Serious Infectious Diseases 155
Injection site reactions resulting from the use of biological therapy in the treatment of moderate-to-severe plaque psoriasis 151
Effectiveness and Safety of Upadacitinib for Adolescents with Atopic Dermatitis in a Real-World Setting 146
Long-Term Efficacy and Safety of Guselkumab in Psoriasis Patients Who Failed Anti-IL17: A Two-Year Real-Life Study 139
The Impact of Psoriasis Treatments on the Risk of Skin Cancer: A Narrative Review 138
Tattooing and hidradenitis suppurativa: stigmatization and camouflage 136
Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience 136
The use of ChatGPT in the dermatological field: a narrative review 135
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients 135
Effectiveness and Safety of Tildrakizumab in Psoriasis Patients Who Failed Anti-IL17 Treatment: A 28-Week Real-Life Study 135
Comment on ‘Anogenital dermatology: challenges in the digital era’ 134
Letter to the editor regarding article "Falotico JM, Gu L, Lipner SR. Not just pimple popping: The utility of hybrid telemedicine models beyond acne management amidst the ongoing COVID-19 pandemic. J Cosmet Dermatol. 2022;10.1111/jocd.15256" 131
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients 131
The Role of Teledermatology During the COVID-19 Pandemic: A Narrative Review 130
Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature 129
Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature 123
Efficacy and Safety of Cemiplimab for the Management of Non-Melanoma Skin Cancer: A Drug Safety Evaluation 122
Hidradenitis Suppurativa Cancer Risk: A Review of the Literature 122
Safety and Efficacy of Covid-19 Vaccination in Patients Undergoing Biological Treatments for Psoriasis 120
Risk Factors for Psoriasis Flares: A Narrative Review 119
Efficacy and Safety of Tildrakizumab in a Patient with Chronic HBV Infection 118
Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature 116
Lichen planus following Covid-19 vaccination: a narrative review 115
Concomitant Severe Psoriasis and Bullous Pemphigoid Induced by COVID-19 115
Efficacy and safety of deucravacitinib for the management of psoriasis: a drug safety evaluation 115
Herpes Zoster and COVID-19 Vaccination: A Narrative Review 114
Dietary intervention in acne management: review of the literature and future prospective 113
The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials 113
Indirect Comparison Between Bimekizumab and Brodalumab for the Management of Moderate to Severe Psoriasis: A 36-Week Real-Life Study 113
Oral Minoxidil for Chemotherapy-Induced Alopecia 112
How Adalimumab Impacts Antibiotic Prescriptions in Patients Affected by Hidradenitis Suppurativa: A 1-Year Prospective Study and Retrospective Analysis 110
Unaddressed Challenges in the Treatment of Cutaneous Melanoma? 110
Very low-calorie ketogenic diet (VLCKD) in the management of hidradenitis suppurativa (Acne Inversa): an effective and safe tool for improvement of the clinical severity of disease. Results of a pilot study 109
Comment on ‘Pityriasis rubra pilaris-like eruption following mRNA COVID-19 vaccine’ 108
Airborne allergic contact dermatitis "by proxy" due to budesonide 108
New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current Knowledge 108
Paradoxical hidradenitis suppurativa induced by adalimumab biosimilar successfully treated with guselkumab in a psoriasis patient. Comment on "Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab" 108
Efficacy and Safety of bimekizumab in psoriasis management in real-life: bio-naïve vs bio-experienced 107
Psoriasis and Molecular Target Therapies: Evidence of Efficacy in Preventing Cardiovascular Comorbidities 105
Biologics for the Management of Erythrodermic Psoriasis: An Updated Review 103
Teledermatology for Common Inflammatory Skin Conditions: The Medicine of the Future? 103
Comment on: “Clinical characteristics of patients with pityriasis rubra pilaris following SARS‐CoV‐2 vaccination” by Gambichler 103
Comment on ‘Permethrin-unresponsive scabies in London, UK: a wake-up call’ 102
Efficacy and safety of spesolimab for the management of generalized pustular psoriasis: a drug safety evaluation 101
A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab 101
Guselkumab-induced vitiligo in a patient with psoriatic arthritis 100
Reply to 'Omalizumab for the management of refractory aquagenic pruritus' 100
The role of teledermatology for the long-term management of stable psoriasis treated with biologics: a survey-based study 100
Comment on: "Associations between hidradenitis suppurativa and dermatological conditions in adults: A national cross-sectional study by Brown et al." 99
The Impact of COVID-19 Vaccination on Inflammatory Skin Disorders and Other Cutaneous Diseases: A Review of the Published Literature 98
Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation 97
Climate change and the role of dermatologists: a call to action 93
Pemphigus and Bullous Pemphigoid Following COVID-19 Vaccination: A Systematic Review 92
Effectiveness, Safety, and Long-Term Continuation Rate Analysis of Dupilumab Treatment in Adolescents with Atopic Dermatitis: A Single-Center Real-Life Retrospective Study 92
ChatGPT and Dermatology: friends or foes? 91
The Past, the Present and the Future of Teledermatology: A Narrative Review 91
An update on the current and emerging pharmacotherapies for basal cell carcinomas 89
Anti-IL-17/23 Drugs for the Treatment of Moderate-to-Severe Hidradenitis Suppurativa in Patients With Concomitant Psoriasis: A Multicenter Retrospective Study 88
Hidradenitis Suppurativa in Elderly Patients: Clinical and Therapeutical Outcomes—A Review of the Literature 88
Reply to ‘Effectiveness, safety and drug survival of oral roflumilast for hidradenitis suppurativa’ by Holgersen et al 87
Comment on 'Development of Chilblains Lesions During the COVID-19 Pandemic is Strongly Associated with Cold Weather: Retrospective Analysis of Patients from a Single Center in the United States' 86
Reply to Borgia et al. Comment on “Marasca et al. Teledermatology and Inflammatory Skin Conditions during COVID-19 Era: New Perspectives and Applications. J. Clin. Med. 2022, 11, 1511” 85
Author Reply to “Comment on ChatGPT and Medical Writing in Dermatology: why should we keep writing?” by Daungsupawong et al 83
Long-Term Efficacy of Guselkumab in an Adolescent Hidradenitis Suppurativa Patients: A Case Report 83
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data 81
Comment on “Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 16-week multicenter retrospective review” 80
Viral Reactivation Following COVID-19 Vaccination: a review of the current literature 80
ChatGPT and dermatology 77
Author Reply to “Comment on ChatGPT and Medical Writing in Dermatology: why should we keep writing?” by Duff et al 75
Injection site reactions after dupilumab or tralokinumab for atopic dermatitis 73
Reply to “Improved clinical effectiveness of adalimumab when initiated with clindamycin and rifampicin in hidradenitis suppurativa” 72
L-Lysine as an Alternative Treatment for Pityriasis Rosea (PR) [Response to Letter] 69
Secukinumab for Severe Hidradenitis Suppurativa in a Patient on Haemodialysis: Efficacy and Safety on 300 mg Every 2 Weeks Administration – A Case Report 67
Reply to “Dalbavancin for the treatment of severe hidradenitis suppurativa” 66
Biological Therapy for Psoriasis in Cancer Patients: An 8-Year Retrospective Real-Life Study 65
Hypergammaglobulinemia in Hidradenitis Suppurativa Patients: A New Emerging Association 64
Management of Advanced Invasive Melanoma: New Strategies 63
Allergic contact dermatitis to petrolatum: An unknown for patch testing 62
Advancing Dermatology: Embracing the Power of Artificial Intelligence 62
Comment on ‘Eosinophilic pustular folliculitis developing at the site of COVID-19 vaccination’ 62
Nail Psoriasis: An Updated Review of Currently Available Systemic Treatments 60
Long-term efficacy and safety of bimekizumab in real-world setting: a 52-week prospective study 56
ChatGPT and Medical Writing in Dermatology: why should we keep writing? 56
Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era? 56
Severe Paradoxical Scalp Psoriasis Induced by Bimekizumab in a Young Multifailure Hidradenitis Suppurativa Patient 53
Comment on ‘Onset of epidermolysis bullosa acquisita under therapy with ustekinumab for the treatment of Crohn disease’ 53
Pityriasis Rosea and Pityriasis Rosea-Like Eruption Following COVID-19 Vaccination: A Narrative Review 52
Guselkumab In A Subset Of Multifailure Patients With Hidradenitis Suppurativa: Real-Word Evidence from Federico II 51
Comment on ‘Oral ivermectin to treat scabies: a comparison of two different regimens’ 51
Hidradenitis suppurativa and bimekizumab: Looking to the future 38
Bimekizumab for Hidradenitis Suppurativa from Trials to Real Life: A Review of the Published Literature 26
Reply to 'Rifampicin and clindamycin for epidermal growth factor receptor inhibitor-related acneiform rash' 25
Long-Term Outcomes of Secukinumab in Moderate-to-Severe Hidradenitis Suppurativa: A Multicentre Cohort Study 17
Reply to ‘Real‐world experience of switching from tralokinumab to lebrikizumab in atopic dermatitis’ 12
Hidradenitis Suppurativa and IL-17 Inhibitors: A Focus on Trials and Real-Life Data 6
Real-World Experience with Upadacitinib in Patients with Atopic Dermatitis and Hidradenitis Suppurativa: A Dual-Center Case Series 2
Totale 9.913
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.290
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.290
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/202383 0 0 0 0 0 10 11 17 3 16 17 9
2023/2024720 13 22 50 18 11 24 16 42 331 40 77 76
2024/20252.993 104 158 35 31 79 237 288 243 201 398 998 221
2025/20265.573 576 873 637 610 729 200 459 362 471 271 203 182
2026/2027544 362 182 0 0 0 0 0 0 0 0 0 0
Totale 9.913